PLASMA Act
HR 6465, the PLASMA Act, amends Medicare Part D's discount program to create a specific phase-in for plasma-derived specialty drugs. It directly affects Medicare Part D beneficiaries who use these drugs and reach their annual out-of-pocket spending limit. The bill establishes a new "specified plasma-derived product percent" to calculate discounted prices for these drugs, based on whether beneficiaries have already met their out-of-pocket threshold for other Part D drugs. This changes how manufacturers' negotiated prices are discounted for plasma-derived products under the existing program, without creating new benefits or altering coverage.
Bill status
in committee
1 of 4 stages cleared
Introduction
Nov 2023
Committee Review
Floor Vote
President
Introduced Nov 21, 2023
Last action Dec 17, 2024
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
4
Key actions
0
Committee
3
Dec 17, 2024
Committee
Referred to the Subcommittee on Health.
lower
Nov 24, 2023
Committee
Referred to the Subcommittee on Health.
lower
Nov 21, 2023
Committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
lower
Nov 21, 2023
Introduced
Introduced in House
lower
1 primary · 7 co-sponsors
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 6465
Scope: US
Hi! I can help you understand HR 6465. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline